Literature DB >> 22739774

Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.

M Levi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22739774     DOI: 10.1160/TH12-05-0330

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  1 in total

1.  Blocking bleeding: reversing anticoagulant therapy.

Authors:  Jack Ansell
Journal:  Nat Med       Date:  2013-04       Impact factor: 53.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.